Kiora Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KPRX and other ETFs, options, and stocks.About KPRX
Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102.
CEOBrian Matthew Strem
CEOBrian Matthew Strem
Employees12
Employees12
HeadquartersEncinitas, California
HeadquartersEncinitas, California
Founded1998
Founded1998
Employees12
Employees12
KPRX Key Statistics
Market cap7.47M
Market cap7.47M
Price-Earnings ratio-0.82
Price-Earnings ratio-0.82
Dividend yield—
Dividend yield—
Average volume51.24K
Average volume51.24K
High today$2.14
High today$2.14
Low today$2.03
Low today$2.03
Open price$2.14
Open price$2.14
Volume26.11K
Volume26.11K
52 Week high$4.18
52 Week high$4.18
52 Week low$1.76
52 Week low$1.76
Stock Snapshot
Kiora Pharmaceuticals(KPRX) stock is priced at $2.07, giving the company a market capitalization of 7.47M. It carries a P/E multiple of -0.82.
As of 2025-12-06, Kiora Pharmaceuticals(KPRX) stock has fluctuated between $2.03 and $2.14. The current price stands at $2.07, placing the stock +2.0% above today's low and -3.3% off the high.
Kiora Pharmaceuticals(KPRX) shares are trading with a volume of 26.11K, against a daily average of 51.24K.
During the past year, Kiora Pharmaceuticals(KPRX) stock moved between $1.76 at its lowest and $4.18 at its peak.
During the past year, Kiora Pharmaceuticals(KPRX) stock moved between $1.76 at its lowest and $4.18 at its peak.
People also own
Based on the portfolios of people who own KPRX. This list is generated using Robinhood data, and it’s not a recommendation.